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1 Introduction 
 
Respiratory distress syndrome (RDS) is a major cause of neonatal morbidity and mortality 
in premature infants. It affects about 1% of all newborns and the incidence is as high as 10-
15% in infants with birth weight under 2500 g (1). RDS is caused by the structural 
immaturity of the lungs and the inadequate levels of surfactant in the alveoli. The incidence 
of RDS decreases as the gestational age of the child rises being 70% before week 30 and 
reducing to 20% for weeks 32-37 (2).  
 
The maturation of the lungs of a fetus can be accelerated or delayed by external factors (3). 
For instance poorly controlled maternal diabetes may delay lung maturation and conditions 
stressful for the fetus such as maternal smoking or hypertension may accelerate it (2). 
Therefore assessing lung maturity only based on gestational age is neither sensitive nor 
specific enough for clinical practice.  
 
1.1 Lecithin/sphingomyelin ratio and phosphatidylglycerol 
Surfactant deficiency is the main cause of RDS whether it is caused by underdevelopment 
of the surfactant system or a genetic deficiency of surfactant-associated proteins. Surfactant 
is a mixture of lipids and proteins that reduces the surface tension on the fluid-air barrier of 
the lung and therefore prevents it from collapsing upon expiration (3). Many different 
methods have been used in assessing fetal lung maturity in the past but measuring the 
lecithin/sphingomyelin (L/S) ratio and the existence of phosphatidylglycerol (PG) in the 
amniotic fluid has been the gold standard of late. As the lungs mature the levels of lecithin 
in the amniotic fluid rise as the levels of sphingomyelin stay steady. PG appears in the 
amniotic fluid late in the maturation process of the lungs and therefore is extremely 
sensitive but has a low specificity. L/S and PG are measured from the amniotic fluid by 
thin-layer chromatography. The cost, slowness and difficulty of this process have created a 
need for a faster and cheaper method.  
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1.2 Lamellar body count 
Lamellar bodies are concentrically layered packages of pulmonary surfactant lipids and 
proteins that upon release from type II alveolar cells help form the surfactant film on the 
inner surface of the lung. The lamellar body count (LBC) of the amniotic fluid rises as the 
lungs mature. (3) These lamellar bodies are the same size as thrombocytes and can 
therefore be counted with a regular cell counter available in every hospital and practically 
free of cost compared with L/S and PG (table 1).  
 
 
 L/S PG Lamellar body 
count 
Cost 120 € Done with L/S 22 € 
Results 1-4 days 1-4 days Same day 
Availability 
 
Volume of amniotic 
fluid needed 
Only in specialized 
hospitals 
 
4 ml 
Only in specialized 
hospitals 
 
Done with L/S 
In all laboratories 
 
 
1-2 ml 
Effect of blood + - -/+ 
Effect of meconium  + - ? 
Table 1. Huslab laboratory manual 
 
 
There have been many studies on the use of LBC compared to L/S and PG in assessing 
fetal lung maturity and LBC has been found to perform either as well as or even slightly 
better than L/S and PG as a predictor of RDS (4-7). This feature combined with its low cost 
and speed has led to a rapid increase in the use of LBC as a primary test in assessing fetal 
lung maturity.  LBC has also been found to predict milder neonatal respiratory problems 
such as transient tachypnea of the newborn (TTN) (8). 
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1.3 Lamellar body count cutoff values 
There have been many studies on the subject of LBC cutoff values for immature and 
mature fetal lungs but they have all been conducted abroad except for one. This has a 
couple of downsides to it. First of all, the LBCs from the same sample differ greatly 
depending on the type of a cell counter they were analyzed with (9). Secondly, some 
laboratories centrifuge the samples as a part of their procedure before testing for LBC while 
others do not and centrifuging is known to decrease the LBC count by approximately 30% 
after centrifugation at 500 g for 5 minutes (10). Thirdly the sample collection method has 
been varied but it has been recommended recently that all samples should be collected by 
amniocentesis or at cesarean section (11). It has also been suggested that higher values 
should be used for the fetuses of diabetic mothers, however, no exact value has been 
established.  
 
The cutoff values currently in use in Women´s Hospital (Helsinki University Central 
Hospital, HUCH) have been derived mainly from the study done in Finland by Joutsi-
Korhonen et al in 2010 (12). This is understandable since their study was done with our 
population and with the Sysmex XE-2100 cell counter still in use today. Yet some 
problems remain. The biggest one is that in their study LBC samples were centrifuged (500 
g for 3 minutes) unlike in practice today yet no changes have been made to the cutoff 
values.  
 
The LBC cutoff values used in Women´s Hospital (HUCH) at the moment are ≤5 xE9 for 
immature and >35 xE9 for mature. Were the LBC to fall in between these values, L/S and 
PG assessment is automatically done for further evaluation. This practice has been in use 
from the beginning of 2009. At the end of 2012 it was estimated that about 90% of the 
samples underwent LBC, L/S and PG testing. As this is neither economical nor practical 
better guidelines for the use of LBC based on local studies are needed. 
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1.4. Aim of the study 
In order to analyze the current situation in the fetal lung maturity assessment in our 
institution, we have performed this study to: 
1. Determine the number and indications of amniocenteses performed for fetal lung 
maturity, 
2. Analyze fetal lung maturity profile (comparison of LBC and phospholipids) 
3. To assess the respiratory condition of the newborns  
4. To develop new reference values and compare the performance of LBC and 
phospholipids  
5. To estimate the costs of both laboratory methods and impact of new references on the 
costs and accuracy of the fetal lung maturity determination 
 
2 Materials and Methods 
 
Data was collected on all patients who had LBC values assessed in Women´s Hospital 
(HUCH) during 2009-2011. Clinical data was obtained from patient records for both the 
mother and child. Patients who had more than seven days between the last amniocentesis 
and delivery were excluded. Twin pregnancies were also excluded because only one study 
was found on how LBC works in multiple pregnancies (13). The institutional review board 
approved the study.  
 
Clinical data was collected on the indications for amniocentesis and labor, the presence of 
diabetes, intrauterine growth retardation, pre-eclampsia, premature rupture of the 
membranes and intra-amniotic infection, the use of antenatal corticosteroids (time of first 
dose in relation to amniocentesis), dates and quantity of amniocentesis, time interval 
between amniocentesis and labor and the results of LBC, L/S and PG tests. Clinical data 
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collected on the fetus included method of birth, gestational age and weight at birth, sex, 
Apgar scores and arterial pH. 
 
All LBC samples were collected by amniocentesis. The amniotic fluid collected was not 
centrifuged or frozen before LBC analysis. After separating the 1 ml needed for LBC the 
rest of the sample was frozen for the potential L/S and PG analysis. The cell counter used 
was Sysmex XE-2100 (Sysmex, Kobe, Japan). L/S and PG values were analyzed with thin 
layer chromatography to be <2, 2 or >2 for L/S and negative, weak positive or positive for 
PG.  
 
After exclusion of the patients who did not meet the study criteria, relevant pregnancy, 
labor and postnatal data were collected from the medical records. The diagnostic criteria 
used for RDS were cyanosis in room air (arterial p02 < 6,7), need for oxygen treatment to 
keep arterial p02 > 6,7 in first three days and typical chest radiograph findings (air 
bronchograms and the so called white out). Other milder respiratory difficulties like 
transient tachypnea of the newborn (TTN) were recorded as well. 
 
2.1 Statistics 
All statistics were calculated with PASW Statistics 18, release 18.0.2, WinWrap Basic. The 
sensitivity and specificity of L/S and PG were estimated with cross tabulation. The 
comparison between the RDS and non-RDS groups was calculated with Independent 
Samples t test or Fisher´s Exact test when appropriate. The sensitivity and specificity values 
for LBC were determined from a Receiver Operating Characteristics curve. 
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3 Results 
 
The final patient group consisted of a total of 183 women and their children. The mean 
gestational age at birth was 35.1 weeks (SD 2,5, range 26-39). There were 61 (33,3%) term 
pregnancies (delivery at 37 weeks or later). The mean gestational age at last amniocentesis 
was 34,7 weeks (SD 2,4, range 25-38). Consecutive amniocenteses were performed to 60 
mothers, 15 mothers had three procedures and one had four consecutive amniocenteses. 
The most common indications for amniotic punctures were erythropoietin assessment in 
macrosomic fetuses (n=90) and intrauterine growth retardation (n=22). Of the 183 LBC 
samples obtained, 161 (88,0%) underwent additional L/S and PG testing. RDS was 
diagnosed in 8 (4,4%) children and 8 others had milder breathing difficulties such as TTN.  
 
The comparison between the group who developed RDS and those that did not revealed 
statistically significant differences in regards to gestational age at birth (p<0,001), birth 
weight (p=0,005), use of antenatal corticosteroids (p=0,033) and incidence of premature 
rupture of membranes (p=0,023).  No statistically significant differences were found 
regarding diabetes of the mothers, intrauterine growth retardation, pre-eclampsia, intra-
amniotic infection or the Apgar scores. 
 
 No RDS RDS 
Mothers n= 175 8 (4,4%) 
Diabetes n= 90 2 
Sex of Fetus M/F 86/88 * 4/4 
Gestational age (weeks)   
   Mean ± SD  35,3 ± 2,2 30,8 ± 4,2 
   Range 27-39 26-36 
Birth weight (g)   
   Mean ± SD 3032 ± 1056 2126 ± 1761 
   Range 550 - 5280 580 - 5330 
Apgar score   
   Mean ± SD 7,83 ± 1,9 7,13 ± 1,5 
   Range 0 - 10 5 - 9 
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 No RDS RDS 
IUGR n= 34 1 
Pre-eclampsia n= 20 2 
PROM n= 4 0 
IAI n= 5 7 
Antenatal corticosteroids n= 
   % of the group 
83 
47,4 
7 
87,5 
Table 3. Clinical data of the 183 pregnancies 
* The sex of one fetus was unclear 
IUGR = intrauterine growth retardation 
PROM = premature rupture of the membrane 
IAI = intra-amniotic infection 
 
 
3.1 Lamellar body count results 
Of all the 183 samples the mean LBC was 23,7 xE9/l (SD 14,9, range 1-90). The values for 
the RDS group were markedly lower (mean 14,0, SD 8,5, range 6-28) than for the non-RDS 
group (mean 24,1, SD 15,0, range 1-90). However, statistically significant difference could 
not be proven because of the small amount of RDS patients (n=8) in this study. The LBC 
values in the group with milder respiratory difficulties had the mean of 16,6 (SD 10,8, 
range 5-31). No statistically significant difference was found between this group and the 
RDS and non-RDS groups. The Receiver Operating Curve (ROC) had the area under the 
curve of 0,726 ± 0,085, p=0,031 (figure 1). Some sensitivity and specificity values derived 
from the curve are shown in table 4. The cutoff point with the highest sensitivity + 
specificity combination occurred at LBC 16,5 xE9 with sensitivity of 75,0% and specificity 
of 65,1%. 
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Table 4. Sensitivity and specificity values derived for LBC derived from the ROC curve. 
 
Figure 1. ROC curve for lamellar body count with respiratory distress syndrome as an 
endpoint. 
 Sensitivity (%) Specificity (%) 
Lamellar body count   
   34,5 100 17,7 
   28,5 100 32,6 
   16,5 75 65,1 
   13,5 50 74,9 
   7,5 25 90,2 
   5,5 0 93,7 
L/S  37,5 90,2 
PG 100 4,6 
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The mature value used in Women´s hospital (HUCH) is >2 for L/S and positive for PG. 
The sensitivity calculated with these values for L/S was 37,5% and specificity 90,2% 
(Table 5). For PG the sensitivity was 100% and specificity 4,6% (table 6). 
 
Table 5  
L/S missing n=22 
 
Table 6. 
PG missing n=22 
 
4 Conclusions 
 
Of all the data variables collected on the mothers, statistically significant differences were 
found in gestational age at birth, birth weight, use of antenatal corticosteroids and incidence 
of premature rupture of membranes between the RDS and non-RDS groups. The RDS 
group had lower gestational age and weight at birth, they got more corticosteroids and had 
higher incidence of PROM. The first three observations are easily explained by the 
mechanism of RDS since its incidence rises as gestational age declines and younger fetuses 
are more likely to get corticosteroid treatment in the event of imminent premature labor. 
 No RDS RDS 
L/S ≤2 15 3 
L/S >2 138 5 
 No RDS RDS 
PG negative  142 8 
PG weak positive 4 0 
PG positive 7 0 
10 
 
PROM also leads usually to an earlier birth of the child regardless of the fetal lung maturity 
status and so RDS would be more common in this group. 
 
4. 1 LBC today and in the future 
The two LBC cutoff values in clinical use at Women´s hospital (HUCH) today are too strict. 
Lowering the mature value from current >35 to >28 would not lower the sensitivity from 
100% but only increase specificity from 17,7% to 32,6%. Raising the immature value from 
≤5 xE9 to <7,5 xE9 would elevate the sensitivity from 0% (sic!) to 25% and only decrease 
the specificity by 1,7% (from 93,7% to 92%). However, even with these changes 114 
(62%) samples would have been additionally tested for L/S and PG. In the three years 
included in this study, Women´s Hospital would have saved about 5640 euros in laboratory 
costs. 
 
The idea of using L/S and PG together to get the predictive accuracy of 100% for 
sensitivity and 92% for specificity sounds optimal. However, the extremely low specificity 
of PG (4,6%) has led to a situation, at least at Women´s Hospital (HUCH), where it is only 
calculated into the clinician´s decision when treating diabetic mothers. In non-diabetic 
pregnancies the decisions are based solely on the L/S value when LBC is in the current 
transitional zone (88% of the time). Based on our study LBC performs better than L/S even 
with a single cutoff value of 16,5 xE9 (sensitivity 75% vs 37,5%, specificity 65,1% vs 
90,2%, respectively). Because sensitivity is much more important in the fetal lung maturity 
evaluation as false immature results only lead to the continuation of the pregnancy we 
recommend the use of LBC as a single RDS prediction method at least for the non-diabetic 
mothers.  
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4.2 Comparison with previous studies 
The major difference in methodology between our study and the study by Joutsi-Korhonen 
et al (12) is that they compared the LBC values with L/S and PG results to specify cutoff 
values as we used RDS as the endpoint to evaluate sensitivity and specificity. As their aim 
was only to substitute one method with another, their LBC values could not reach better 
predictive values than L/S and PG. The sensitivity for L/S in this study was significantly 
lower than in other recent studies (37,5% vs 62%-100%). This is at least partly because 
some hospitals use ≥2 as a mature value as we use >2. There is also the influence of the 
laboratorian that factors into the results as L/S is a visually semi-quantitatively measured 
value. Other predictive values for L/S and PG were in line with recent studies. 
 
A recent meta-analysis by Besnard et al (4) on the same subject as our study once again 
declared the LBC to perform at least as well or slightly better than L/S. They also combined 
12 studies with sensitivity and specificity values calculated for LBC (appendix 2), which 
are slightly higher than in ours but so are the L/S values as well. Regardless that the studies 
were done with different cell counters, diagnostic criteria for RDS and patient exclusion 
criteria and therefore were not entirely compatible, they also ended up recommending the 
use of LBC as a single method for fetal lung maturity evaluation. Visnjevac et al (14) had 
similar results with sensitivity of 82,4% and specificity of 64,4% and also recommended 
the one cutoff method for LBC evaluation.  
 
4.3. Future studies 
The difficulty in this study was the low incidence of RDS (8 cases, 4,4% of the study 
group). Though this is an indicator of good obstetric and neonatal care it also makes it very 
difficult to get statistically significant results in a study setting like ours. We are still not 
aware of the incidence of RDS in the whole neonatal population in our institution. 
 
Even though RDS and non-RDS groups did not differ significantly regarding diabetes, 
some studies have shown that the LBC values of diabetic mothers are higher at a certain 
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gestational age when compared with non-diabetic mothers. It might be necessary to raise 
the LBC cutoff for this subgroup, but the subject still requires more research.  
 
As always, it is not enough to evaluate a method only in theory but also in clinical practice. 
The use of LBC as a first line fetal lung maturity test has been the standard protocol for 4 
years now in Women´s hospital and no additional evaluation on the method has been done 
during this time. Even though LBC by itself is much cheaper, faster and accessible method, 
if 88% of the amniotic fluid samples undergo L/S and PG testing as well all the benefits are 
lost. This also creates distrust towards the LBC test and confusion about the most probable 
clinical outcome when the results differ from each other. This is an additional reason why a 
single method for evaluating fetal lung maturity would be preferable and we suggest the 
LBC for this role. It would give clinicians faster, more reliable and cheaper method for the 
biochemical assessment of the fetal lung maturity and possibility for optimization of the 
delivery decision. 
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Appendix 2 
 
Study Patients 
n= 
Number 
of cutoff 
values 
Cutoff 
value* 
Prevalence 
of RDS 
Sensitivity Specificity 
Abd El Aal 
(2005) 
73 4 18000 0,32 0,78 1,00 
Bahasadri 
(2005) 
104 2 45000 0,22 0,99 0,98 
Beinlich 
(1999) 
21 1 30000 0,29 0,83 0,67 
Chapman 
(2004) 
88 6 25000 0,16 0,93 0,88 
Ghidini 
(2005) 
102 1 37000 0,17 0,94 0,64 
Haymond 
(2006) 
184 2 50000 0,07 0,92 0,60 
Karcher 
(2005) 
219 1 30000 0,06 0,85 0,75 
Khazardoost 
(2005) 
80 1 50000 0,25 0,85 0,70 
Neerhof 
(2001) 
833 2 N/A 0,12 0,89 0,64 
Piazze I 
(1999) 
92 1 20000 0,21 0,95 0,73 
Piazze II 
(2005) 
178 1 22000 0,34 0,73 0,82 
Roiz-
Hernandez 
(2002) 
264 3 57000 0,15 0,92 0,71 
Modified from the study Lecithin/sphingomyelin ratio and lamellar body count for fetal 
lung maturity: a meta-analysis by Anouk E. Besmard et al, 2013 (4) 
 
* Performance of the LBC ratio in the prediction of RDS. If a study reported on multiple 
cut-off values, only one is shown. 
 
 
